Daybue
Evidence Grade A — Regulatory approved. 72 published studies. 13 registered clinical trials.
Loading...
Trofinetide (sold as Daybue) is the first and only treatment ever approved for Rett syndrome — a rare genetic neurological disorder that primarily affects girls, causing severe impairments in communication, hand function, and movement. Taken as an oral liquid twice daily, it does not cure Rett syndrome but helps manage symptoms and improve quality of life for patients and their caregivers.
72 published studies: 46 human, 1 animal, 4 in-vitro, 23 reviews
Trofinetide is marketed as Daybue (Acadia Pharmaceuticals, approved March 2023). It is the first FDA-approved treatment for Rett syndrome, a condition that affects an estimated 15,000–20,000 individuals in the US. Previously, treatment was limited to managing individual symptoms.
In the LAVENDER trial, trofinetide showed significant improvement on both a clinician-assessed severity scale and a caregiver-assessed behaviour questionnaire compared to placebo. The most common side effects are diarrhoea (approximately 80%) and vomiting. While the improvements are meaningful to patients and families, trofinetide does not cure Rett syndrome — it is a symptom management treatment that requires ongoing daily dosing.
Trofinetide is based on a tiny three-amino-acid fragment that is naturally cleaved from IGF-1 in the brain. Despite this origin, it does not work through IGF-1 receptors. Instead, it appears to reduce neuroinflammation and normalise the abnormal brain signalling caused by mutations in the MECP2 gene that underlie Rett syndrome. The exact molecular targets are not fully characterised, but the compound modulates pathways related to inflammation, excitotoxicity, and synaptic function in the brain.
The LAVENDER trial showed significant improvement on both a clinician-assessed severity scale and a caregiver-assessed behaviour questionnaire compared to placebo. The effect sizes are modest, but for a condition that previously had no pharmacological treatment at all, any measurable improvement is meaningful to families. The most challenging side effect is diarrhoea, which occurs in approximately 80% of patients, though it is typically manageable. Vomiting is also common. An open-label extension study shows sustained benefit through 32 months of treatment. Rett syndrome affects an estimated 6,000–9,000 individuals in the US. Gene therapy approaches targeting restoration of the underlying MECP2 gene defect represent the next frontier for this condition.
Cognitive Function in Rett Syndrome During Trofinetide Treatment
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
Open-Label Extension Study of Trofinetide for Rett Syndrome
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
FDA ORIG 1
FDA SUPPL 3
FDA SUPPL 1
Health Canada Market Authorisation
FDA SUPPL 7
FDA SUPPL 6
FDA ORIG 1
Pinealon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. The evidence base consists of in vitro cell studies and animal experiments published primarily by the originating research group. As with other Khavinson bioregulator peptides, the proposed mechanisms and the underlying theoretical framework have not been evaluated through conventional Western regulatory processes. Products available through unregulated channels lack pharmaceutical quality assurance.
Selank is approved in Russia for anxiety-related conditions. It has not been approved by the FDA, EMA, or other major Western regulatory agencies. The key clinical study (62 patients) compared Selank to a benzodiazepine in generalised anxiety disorder and reported comparable effects. Published clinical studies are predominantly Russian and have not undergone Western regulatory review. The evidence base does not meet FDA or EMA approval standards. Its regulatory status is limited to Russia and certain former Soviet states.
Semax is approved in Russia for stroke recovery and cognitive conditions. It has not been approved by the FDA, EMA, or other major Western regulatory agencies, and the clinical evidence base has not undergone Western regulatory review. Published clinical studies are predominantly Russian. The largest published study (110 stroke patients) reported correlations between treatment and BDNF levels. The evidence does not meet the standards typically required for FDA or EMA approval. Its regulatory status is limited to Russia and certain former Soviet states.
